SAN DIEGO (AP) – Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. said that they are discontinuing development of pramlintide/metreleptin, a combination therapy to treat obesity.
The companies said the decision was based on a commercial assessment. Amylin’s senior vice president of research, Christian Weyer, said that in the future, the hope is to develop a similar treatment with “less frequent dosing.”
Neither company expects to revise their latest fiscal 2011 guidance because of the development stoppage.
Date: August 4, 2011
Source: Associated Press
Filed Under: Drug Discovery
